Patent Tracker
Applications for patents related to psychedelics have boomed in recent years. Nonprofits, pharmaceutical companies, startups, and academic institutions are all jockeying to patent specific psychedelic compounds and formulations. To help keep tabs on the status of patent applications as they wind their way through the U.S. Patent and Trademark’s review process, BCSP has collaborated on a patent tracker with Psychedelic Alpha, an independent media outlet, community and consultancy firm in the psychedelic field, and Calyx Law, a patent law boutique focusing on cannabis and psychedelics related IP. Read more about the history and process of psychedelic patents here.
1357 Patents
Psilocybin & Psilocin
Title
Methods of treating disorders with a psilocybin analog
Subject Matter
Methods of treating various diseases, disorders, and conditions, such as depressive disorders (e.g., Major Depressive Disorder (MDD)), substance use disorders, anxiety disorders, eating disorders, pain, and headache disorders via administration of deuterated psilocin and pharmaceutically acceptable salts, polymorphs, or solvates thereof.
LSD
Title
Compositions comprising lysergic acid diethylamide, optionally in combination with N-acylethanolamines and uses thereof
Subject Matter
Pharmaceutical compositions comprising lysergic acid diethylamide (LSD), or a salt thereof, and combinations of LSD and an N-acylethanolamine, and their use in methods of treating alcoholism, depression, anxiety, headaches, and pain.
Owner
Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
Patent Number
US20260256716Priority Date
03.10.2023
Status
Published
Psilocybin & Psilocin
Title
Psilocybin compositions
Subject Matter
Methods and compositions for enhancing neurogenesis, resolving neuropathy and improving neurological health and functioning using fungal extracts and their active ingredients, including species of mushrooms and mycelia containing psilocybin and psilocin, combined with erinacines and hericenones or fungal extracts containing those active ingredients, with the addition of nicotinic acid. The compositions may optionally be combined with nervine plants.
Ibogaine
Title
Ibogaine and noribogaine prodrugs and methods of use
Subject Matter
Ibogaine and noribogaine prodrugs, pharmaceutically acceptable salts thereof, and compositions thereof, useful for treating various conditions, including alcoholism, substance abuse disorder, and opioid use disorder.
Psilocybin & Psilocin
Title
Psychedelic lipid nanoparticles for intranasal administration
Subject Matter
Compositions containing active ingredient compounds that exhibit a psychedelic effect in a mammal, such as a human patient in need of treatment with such compounds.
MDMA
Title
Compositions comprising 3,4-methylenedioxymethamphetamine, optionally in combination with N-acylethanolamines, and uses thereof
Subject Matter
Pharmaceutical compositions comprising 3,4-methylenedioxymethamphetamine (MDMA) and combinations of MDMA and N-acylethanolamines, and their use in methods of treating post-traumatic stress disorder (PTSD), anxiety, and eating disorders
Psilocybin & Psilocin
Title
Dephosphorylation-controlled extraction of phosphorylatable psychoactive alkaloids
Subject Matter
The extraction of psychoactive compounds from fungus for use in medicine.
LSD
Title
Compositions and uses thereof
Subject Matter
Compositions for use in the treatment, management or amelioration of FMR1 mediated autism and Fragile X Syndrome (FXS), wherein the composition comprises one or more tryptophans or derivatives thereof.
Psilocybin & Psilocin
Title
Composition comprising non-phosphorylated tryptamine
Subject Matter
A composition comprising at least one psychedelic non-phosphorylated tryptamine, at least one antioxidant, and at least one supplement selected from an amino acid, a vitamin, theobromine, caffeine, resveratrol, gamma aminobutyric acid and combinations thereof.
Ibogaine
Title
Ibogaine treatment for lesion reduction and neural structural changes
Subject Matter
A method for inducing lesion reduction in a patient in need thereof and/or Apparent Diffusion Coefficient (ADC) values, the method comprising administering to the patient a therapeutically effective amount of ibogaine, ibogaine derivative, or a pharmaceutically acceptable salt and/or solvate thereof.
Owner
Ambio Life Sciences Inc
Patent Number
WO2026107611Priority Date
11.25.2024
Status
PCT Published
Page 1 of 136